「platelet」の共起表現一覧(1語右で並び替え)
該当件数 : 113件
hospholipases, including phospholipase A2 and | platelet activating factor acetylhydrolase |
It may function as a blood | platelet activation marker. |
g time in mice and protected against systemic | platelet activation and thrombosis. |
inhibitors of adenosine diphosphate-mediated | platelet activation and aggregation. |
It itself is not involved in | platelet activation and aggregation in case of a wound |
ion of smooth muscle tone and blood pressure, | platelet activation, and vascular cell signaling. |
, Granule Membrane Protein 140 (GMP-140), and | Platelet Activation-Dependent Granule to External Memb |
GP Ib-IX-V complex to VWF facilitates initial | platelet adhesion to vascular subendothelium after vas |
for von Willebrand factor (VWF), and mediates | platelet adhesion in the arterial circulation. |
tonin and epinephrine reuptake to that of the | platelet aggregation response to these amines has show |
DHA supplementation has been shown to reduce | platelet aggregation in vegetarians, but a direct link |
Indobufen is a | platelet aggregation inhibitor. |
Cloricromen is a | platelet aggregation inhibitor. |
Ditazole is a | platelet aggregation inhibitor. |
It inhibits | platelet aggregation and is a direct arterial vasodila |
It blocks thromboxane induced | platelet aggregation and vasoconstriction. |
he ratio of TxA2/PGI2 could lead to increased | platelet aggregation and dysregulation of platelet hom |
The relationship between inhibition of | platelet aggregation and clinical activity has not bee |
Adrenaline induces | platelet aggregation and so does hepatocyte growth fac |
Platelet aggregation gradually returns to baseline val | |
Prasugrel produces inhibition of | platelet aggregation to 20 μM or 5 μM ADP, as measured |
ound on platelets that is required for normal | platelet aggregation and adherence to the endothelium. |
In practice, | platelet aggregation gradually returns to normal about |
Honokiol inhibits | platelet aggregation in rabbits in a dose-dependent ma |
Mean steady-state inhibition of | platelet aggregation was about 70% following 3 to 5 da |
0% of patients had at least 50% inhibition of | platelet aggregation by 1 hour. |
Triflusal is a | platelet aggregation inhibitor that was discovered and |
It also sometimes is used to reduce | platelet aggregation by inhibiting degranulation of pl |
precursor for prostaglandin-3 (which inhibits | platelet aggregation), thromboxane-3, and leukotriene- |
next dose resulted in increased inhibition of | platelet aggregation, but not greater than that typica |
It does not inhibit | platelet aggregation, where PGI2 does. |
It inhibits | platelet aggregation, and may also be useful in the tr |
degradation products, D-dimer, thrombin time, | platelet aggregation, or |
diator of many leukocyte functions, including | platelet aggregation, inflammation, and anaphylaxis. |
n found to inhibit histamine H1 receptors and | platelet aggregation, and acts as an opioid analgesic. |
r to shiitake mushrooms, lenthionine inhibits | platelet aggregation, so it is a promising treatment f |
alpha-granules of activated platelets during | platelet aggregation, and promotes blood coagulation b |
of some kind of leukemia cell lines and human | platelet aggregation. |
in I2), a potent vasodilator and inhibitor of | platelet aggregation. |
e A2, a potent vasoconstrictor and inducer of | platelet aggregation. |
ivation of new platelets as well as increases | platelet aggregation. |
Glycoprotein Ib ( | platelet), alpha polypeptide (GP1BA) also known as CD4 |
f Differentiation 226), PTA1 (outdated term, ' | platelet and T cell activation antigen 1') or DNAM-1 ( |
events, such as neural vesicle exocytosis and | platelet and red-cell aggregation. |
Triflusal is a selective | platelet antiaggregant through; |
sildenafil may be the basis for the enhanced | platelet antiaggregatory activity of nitric oxide obse |
Human | platelet antigens (HPA) are polymorphisms in platelet |
The | platelet as a sponge: a review. |
n generated, then activation of platelets and | platelet associated cofactors occurs. |
Glycoprotein Ib ( | platelet), beta polypeptide (GP1BB) also known as CD42 |
It is used to prevent | platelet clumping in blood samples. |
nated RBCs, RBC fragments, giant platelets or | platelet clumps. |
es supplying blood to the legs and decreasing | platelet coagulation. |
after two weeks, a fall in the hemoglobin and | platelet count and an increase in MCV (mean corpuscula |
platelet count | |
Low blood | platelet count which can result in bleeding or bruisin |
osage determined by analysis of the patient's | platelet count at the time of treatment. |
ith great caution, as a rapid decrease in the | platelet count may occur, possibly leading to bleeding |
some hereditary forms of thrombocytosis (high | platelet count) and in some cases of leukemia. |
istic lesions in the liver, rapidly declining | platelet count, and highly elevated SGOT levels. |
The oil has been shown to cause a lowered | platelet count. |
est, which takes fifteen minutes, is based on | platelet count; dengue sufferers have 100,000 or lower |
nd cirrhosis due to hepatitis C (in which low | platelet counts may be a contraindication for interfer |
dence that it may cause a smaller decrease in | platelet counts than ibritumomab tiuxetan does. |
oblems are a complete blood count (especially | platelet counts), APTT (activated partial thromboplast |
that lead to thrombocytopenia (abnormally low | platelet counts). |
ipants), moderate thrombocytopenia (decreased | platelet counts, seen in one third of patients), and m |
confirmed that administration could increase | platelet counts. |
Thromboxane A synthase 1 ( | platelet, cytochrome P450, family 5, subfamily A), als |
entially leading to thrombocytopenia or blood | platelet deficiency and/or leukopenia or white blood c |
S), stem cell factor receptor (SCFR/KIT), and | platelet derived growth factor receptors (PDGFRs). |
targets, including VEGFR-1, VEGFR-2, VEGFR-3, | platelet derived growth factor receptor (PDGFR), and c |
in American Foxhounds is thrombocytopathy, or | platelet disease. |
syndrome, velocardiofacial syndrome and giant | platelet disorder. |
ctor 1, platelet-derived growth factor, TGFβ, | platelet factor 4 (which is a heparin-binding chemokin |
Platelet factor 4 (PF4) is a small cytokine belonging | |
Platelet factor-4 is a 70-amino acid protein that is r | |
Platelet factors reinforce local vasoconstriction and | |
However, its effects on | platelet function can be seen for up to 48 hours after |
Oral agents often used to alter/suppress | platelet function include: aspirin, clopidogrel, cilos |
unlike ketorolac, parecoxib has no effect on | platelet function and therefore does not promote bleed |
closely resembles that of CD43 and the human | platelet glycoprotein GpIb-alpha both of which have an |
Human | platelet glycoprotein V (GP5) is a part of the Ib-V-IX |
sociation of the alpha and beta subunits with | platelet glycoprotein IX and platelet glycoprotein V. |
Platelet glycoprotein IX (GP9) is a small membrane gly | |
sociation of the alpha and beta subunits with | platelet glycoprotein IX (GP9; MIM 173515) and GP5. |
Platelet glycoprotein Ib (GPIb) is a heterodimeric tra | |
n of the alpha and beta subunits with GP9 and | platelet glycoprotein V (GP5; MIM 173511).[supplied by |
Maximum | platelet inhibition was about 80% (Figure 2). |
It should also be noted that increasing | platelet inhibition could increase bleeding risk. |
minimally invasive procedure surgery known as | platelet injection fat transfer which transferred fat |
ively charged surfaces (such as glass, active | platelet membrane, sometimes cell membrane of monocyte |
V Glover, M Sandler:Psychiatric morbidity and | platelet monoamine oxidase activity in cancer patients |
senck (1992b) has claimed that a low level of | platelet monoamine oxidase may be the biological marke |
ond step,mechanical blockage of the hole by a | platelet plug. |
volved in leukocyte transmigration, and (3) a | platelet receptor. |
rimary endpoint of a protocol-defined durable | platelet response in nonsplenectomized or splenectomiz |
hospital researches areas such as the use of | platelet rich plasma to promote the healing of injurie |
Hold the bag of | Platelet Rich Plasma horizontally, approximately 12-30 |
One is a | platelet shape with low aspect ratio and the second is |
Since the average | platelet size is larger when the body is producing inc |
alent complex with glycoprotein Ib (GP Ib), a | platelet surface membrane glycoprotein complex that fu |
Glycoprotein Ib (GP Ib) is a | platelet surface membrane glycoprotein composed of a h |
Platelet swirling is a noninvasive method for testing | |
Platelet swirling is caused by light diffraction due t | |
Gray | platelet syndrome has an autosomal dominant pattern of |
Gray | platelet syndrome (GPS), or platelet alpha-granule def |
deficiency of alpha granules is known as grey | platelet syndrome. |
a, post-transfusion purpura and some cases of | platelet transfusion refractoriness to infusion of don |
tigen system, implicated in refractoriness to | platelet transfusion, neonatal alloimmune thrombocytop |
Mean | platelet volume (MPV) is a machine-calculated measurem |
A typical range of | platelet volumes is 9.7-12.8 |
national Society of Blood Transfusion (ISBT), | platelet working party to overcome problems generated |
こんにちは ゲスト さん
ログイン |
Weblio会員(無料)になると 検索履歴を保存できる! 語彙力診断の実施回数増加! |
こんにちは ゲスト さん
ログイン |
Weblio会員(無料)になると 検索履歴を保存できる! 語彙力診断の実施回数増加! |